^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imjudo (tremelimumab-actl)

    i
    Other names: CP-675206, CP-675,206, CP-675, PF-06753388, CP 675, CP675, PF 06753388, PF06753388, CP675206, CP 675206
    Company:
    AstraZeneca, Pfizer
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    3d
    ALICE: Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=196, Recruiting, UNICANCER | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • oxaliplatin
    6d
    ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, University of California, Irvine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date • Checkpoint inhibition • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    7d
    A single-arm, single-center clinical study of toripalimab as adjuvant therapy for high-risk clear cell renal cell carcinoma after radical nephrectomy (ChiCTR2500115679)
    P=N/A, N=100, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • Imjudo (tremelimumab-actl)
    7d
    Exploratory clinical study of late-stage colorectal cancer treated with the combination of durvalumab, cetuximab, and β-blockers (ChiCTR2600116223)
    P4, N=59, Recruiting, Shanghai East Hospital; Shanghai East Hospital
    New P4 trial
    |
    Erbitux (cetuximab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    9d
    DANUBE : Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer (clinicaltrials.gov)
    P3, N=1126, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 underexpression • PD-L1 negative
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab-actl)
    9d
    Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    LDH elevation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    9d
    RECON: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov)
    P2, N=39, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
    10d
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    11d
    Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy. (PubMed, Int J Biol Macromol)
    Nanotherapeutics like PIR NPs, ThermoDox, and liposomal drug formulations improve drug stability, delivery, and specificity, providing controlled release and reduced toxicity. The integration of CAR-T therapy with ACPs, nanomedicine, and dual-checkpoint blockade such as tremelimumab-durvalumab, and nivolumab-ipilimumab demonstrate improved tumour regression and survival outcomes. Combination strategies that modulate ROS levels, inhibit angiogenesis, and utilize peptide-drug conjugates show promise in preclinical and early clinical studies. This review highlights the therapeutic synergy of next-generation peptide, cellular, and nanoplatform-based therapies in enhancing outcomes for advanced HCC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • GPC3 (Glypican 3)
    |
    TP53 mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • ThermoDox (lyso-thermosensitive liposomal doxorubicin)
    11d
    Significance of Measuring Interferon-γ-Induced Protein-10 Levels in Patients Receiving Systemic Therapies for Unresectable Hepatocellular Carcinoma. (PubMed, Oncology)
    IP-10 levels may be useful predictors of therapeutic response in patients receiving AB or DT therapy. .
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    16d
    CAMILLA: Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (clinicaltrials.gov)
    P1/2, N=117, Recruiting, Anwaar Saeed | Trial completion date: Jan 2028 --> Jun 2029 | Trial primary completion date: Jan 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    RAS wild-type
    |
    Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)
    16d
    Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)